Souvenaid®: A new approach to management of early Alzheimer’s disease View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-11-04

AUTHORS

C. W. Ritchie, J. Bajwa, G. Coleman, K. Hope, R. W. Jones, M. Lawton, M. Marven, P. Passmore

ABSTRACT

Synaptic loss correlates closely with cognitive deficits in Alzheimer’s disease and represents a new target for intervention. Souvenaid® is the first medical nutrition product to be designed to support synapse formation and function in early Alzheimer’s disease, and has undergone an extensive, 12-year development programme. The relatively large amount of clinical data available for Souvenaid® is unusual for a medical nutrition product. Souvenaid® contains omega-3 polyunsaturated fatty acids (docosahexaenoic acid and eicosapentaenoic acid), uridine (as uridine monophosphate) and choline which are nutritional precursors required for synaptic membrane phospholipid synthesis, together with phospholipids and other cofactors. Souvenaid® has demonstrated cognitive benefits in patients with mild Alzheimer’s disease but not in patients with mild-to-moderate Alzheimer’s disease. Two randomised, double-blind, controlled trials (duration 12 and 24 weeks) in patients with mild Alzheimer’s disease untreated with acetylcholinesterase inhibitors and/or memantine have demonstrated that Souvenaid® is well tolerated and improves episodic memory performance. The daily intake of Souvenaid® has not been associated with any harmful effects or interactions with medications and none are anticipated. The ongoing, 24-month, European Union-funded LipiDiDiet trial in subjects with prodromal Alzheimer’s disease is evaluating the potential benefits of Souvenaid® on memory and in slowing progression to Alzheimer’s dementia. If Souvenaid® induces synaptogenesis and improved synaptic function, it may provide benefits in other clinical conditions characterised by neurodegeneration. A number of trials are ongoing and planned to evaluate the potential wider benefits of Souvenaid®. More... »

PAGES

291-299

References to SciGraph publications

  • 2011-10. Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer’s disease: Secondary analyses from a randomized, controlled trial in THE JOURNAL OF NUTRITION, HEALTH & AGING
  • 2012-09-28. Challenges in managing the diet of older adults with early-stage Alzheimer dementia: A caregiver perspective in THE JOURNAL OF NUTRITION, HEALTH & AGING
  • 2013-05-28. Caregiver Health: Health of Caregivers of Alzheimer’s and Other Dementia Patients in CURRENT PSYCHIATRY REPORTS
  • 2006-04. Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3 in NATURE
  • 2006-11. Vitamin B12, a chlorophyll-related analog to pheophytin a from marine brown algae, promotes neurite outgrowth and stimulates differentiation in PC12 cells in CYTOTECHNOLOGY
  • 2003-08. Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer’s disease in JOURNAL OF NEURAL TRANSMISSION
  • 1998-05. Effects of Marine Fish Oils on the Anticoagulation Status of Patients Receiving Chronic Warfarin Therapy in JOURNAL OF THROMBOSIS AND THROMBOLYSIS
  • 2007-05-07. Synapse formation on neurons born in the adult hippocampus in NATURE NEUROSCIENCE
  • 1998-09. Differential Diagnosis of the Major Progressive Dementias and Depression in Middle and Late Adulthood: A Summary of the Literature of the Early 1990s in NEUROPSYCHOLOGY REVIEW
  • 2012-08. Fruit, vegetables and prevention of cognitive decline or dementia: A systematic review of cohort studies in THE JOURNAL OF NUTRITION, HEALTH & AGING
  • 2001-07. Brain Membrane Phospholipid Alterations in Alzheimer's Disease in NEUROCHEMICAL RESEARCH
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s12603-013-0411-2

    DOI

    http://dx.doi.org/10.1007/s12603-013-0411-2

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1034591338

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/24626757


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1111", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Nutrition and Dietetics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Alzheimer Disease", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Choline", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cholinesterase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease Progression", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Docosahexaenoic Acids", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Double-Blind Method", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Eicosapentaenoic Acid", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "European Union", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Memantine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Memory, Episodic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prodromal Symptoms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Randomized Controlled Trials as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Synapses", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Uridine Monophosphate", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Imperial College, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.7445.2", 
              "name": [
                "Department of Medicine, Imperial College, London, UK", 
                "Department of Medicine, Imperial College, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ritchie", 
            "givenName": "C. W.", 
            "id": "sg:person.0715446716.30", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715446716.30"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Conway Medical Centre, Plumstead, London, UK", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Conway Medical Centre, Plumstead, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bajwa", 
            "givenName": "J.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "London, UK", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Coleman", 
            "givenName": "G.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Dementia Services Development Centre, University of Stirling, Stirling, UK", 
              "id": "http://www.grid.ac/institutes/grid.11918.30", 
              "name": [
                "Dementia Services Development Centre, University of Stirling, Stirling, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hope", 
            "givenName": "K.", 
            "id": "sg:person.01056304631.29", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056304631.29"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Research Institute for the Care of Older People, Royal United Hospital, Bath, UK", 
              "id": "http://www.grid.ac/institutes/grid.416091.b", 
              "name": [
                "Research Institute for the Care of Older People, Royal United Hospital, Bath, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Jones", 
            "givenName": "R. W.", 
            "id": "sg:person.01320561246.23", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320561246.23"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "London, UK", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lawton", 
            "givenName": "M.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Oxford Health NHS Foundation Trust, Oxford, UK", 
              "id": "http://www.grid.ac/institutes/grid.451190.8", 
              "name": [
                "Oxford Health NHS Foundation Trust, Oxford, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Marven", 
            "givenName": "M.", 
            "id": "sg:person.0603772166.26", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603772166.26"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Centre for Public Health, Queens University, Belfast, UK", 
              "id": "http://www.grid.ac/institutes/grid.4777.3", 
              "name": [
                "Centre for Public Health, Queens University, Belfast, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Passmore", 
            "givenName": "P.", 
            "id": "sg:person.0751705456.81", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751705456.81"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1023/a:1025628925796", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050886881", 
              "https://doi.org/10.1023/a:1025628925796"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11920-013-0367-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017268113", 
              "https://doi.org/10.1007/s11920-013-0367-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1008852127668", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008832069", 
              "https://doi.org/10.1023/a:1008852127668"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12603-011-0339-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044372203", 
              "https://doi.org/10.1007/s12603-011-0339-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10616-006-9038-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045801968", 
              "https://doi.org/10.1007/s10616-006-9038-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1011603916962", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047542537", 
              "https://doi.org/10.1023/a:1011603916962"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12603-012-0385-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009103358", 
              "https://doi.org/10.1007/s12603-012-0385-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature04598", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008587713", 
              "https://doi.org/10.1038/nature04598"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00702-003-0007-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042189844", 
              "https://doi.org/10.1007/s00702-003-0007-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nn1908", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041228661", 
              "https://doi.org/10.1038/nn1908"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12603-012-0097-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040649409", 
              "https://doi.org/10.1007/s12603-012-0097-x"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2013-11-04", 
        "datePublishedReg": "2013-11-04", 
        "description": "Synaptic loss correlates closely with cognitive deficits in Alzheimer\u2019s disease and represents a new target for intervention. Souvenaid\u00ae is the first medical nutrition product to be designed to support synapse formation and function in early Alzheimer\u2019s disease, and has undergone an extensive, 12-year development programme. The relatively large amount of clinical data available for Souvenaid\u00ae is unusual for a medical nutrition product. Souvenaid\u00ae contains omega-3 polyunsaturated fatty acids (docosahexaenoic acid and eicosapentaenoic acid), uridine (as uridine monophosphate) and choline which are nutritional precursors required for synaptic membrane phospholipid synthesis, together with phospholipids and other cofactors. Souvenaid\u00ae has demonstrated cognitive benefits in patients with mild Alzheimer\u2019s disease but not in patients with mild-to-moderate Alzheimer\u2019s disease. Two randomised, double-blind, controlled trials (duration 12 and 24 weeks) in patients with mild Alzheimer\u2019s disease untreated with acetylcholinesterase inhibitors and/or memantine have demonstrated that Souvenaid\u00ae is well tolerated and improves episodic memory performance. The daily intake of Souvenaid\u00ae has not been associated with any harmful effects or interactions with medications and none are anticipated. The ongoing, 24-month, European Union-funded LipiDiDiet trial in subjects with prodromal Alzheimer\u2019s disease is evaluating the potential benefits of Souvenaid\u00ae on memory and in slowing progression to Alzheimer\u2019s dementia. If Souvenaid\u00ae induces synaptogenesis and improved synaptic function, it may provide benefits in other clinical conditions characterised by neurodegeneration. A number of trials are ongoing and planned to evaluate the potential wider benefits of Souvenaid\u00ae.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s12603-013-0411-2", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1021574", 
            "issn": [
              "1279-7707", 
              "1760-4788"
            ], 
            "name": "The journal of nutrition, health & aging", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "3", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "18"
          }
        ], 
        "keywords": [
          "early Alzheimer's disease", 
          "Alzheimer's disease", 
          "mild Alzheimer's disease", 
          "medical nutrition products", 
          "nutrition products", 
          "moderate Alzheimer's disease", 
          "prodromal Alzheimer's disease", 
          "LipiDiDiet trial", 
          "synaptic loss", 
          "Controlled Trials", 
          "Souvenaid", 
          "clinical data", 
          "clinical conditions", 
          "Alzheimer's dementia", 
          "synaptic function", 
          "synapse formation", 
          "cognitive deficits", 
          "daily intake", 
          "disease", 
          "patients", 
          "nutritional precursors", 
          "episodic memory performance", 
          "acetylcholinesterase inhibitors", 
          "new targets", 
          "trials", 
          "number of trials", 
          "dementia", 
          "cognitive benefits", 
          "fatty acids", 
          "harmful effects", 
          "potential benefits", 
          "phospholipid synthesis", 
          "membrane phospholipid synthesis", 
          "memory performance", 
          "medications", 
          "memantine", 
          "mild", 
          "synaptogenesis", 
          "intake", 
          "neurodegeneration", 
          "progression", 
          "benefits", 
          "intervention", 
          "inhibitors", 
          "deficits", 
          "choline", 
          "subjects", 
          "phospholipids", 
          "function", 
          "target", 
          "management", 
          "loss", 
          "uridine", 
          "effect", 
          "acid", 
          "wider benefits", 
          "program", 
          "potential wider benefits", 
          "data", 
          "cofactor", 
          "number", 
          "development programs", 
          "large amount", 
          "memory", 
          "products", 
          "amount", 
          "precursors", 
          "conditions", 
          "new approach", 
          "synthesis", 
          "formation", 
          "interaction", 
          "approach", 
          "Union", 
          "European Union", 
          "performance", 
          "first medical nutrition product", 
          "synaptic membrane phospholipid synthesis", 
          "induces synaptogenesis"
        ], 
        "name": "Souvenaid\u00ae: A new approach to management of early Alzheimer\u2019s disease", 
        "pagination": "291-299", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1034591338"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s12603-013-0411-2"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "24626757"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s12603-013-0411-2", 
          "https://app.dimensions.ai/details/publication/pub.1034591338"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-01-01T18:29", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_586.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s12603-013-0411-2"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12603-013-0411-2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12603-013-0411-2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12603-013-0411-2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12603-013-0411-2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    320 TRIPLES      22 PREDICATES      134 URIs      114 LITERALS      24 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s12603-013-0411-2 schema:about N0a07c84e327c41058b74522ed0a7128a
    2 N12c075b93b194ef093f98b75fff6b73e
    3 N26b38e38ce964a2891aee3e226fe63c3
    4 N4b2ba9e7b54f4960a5a9a6506857baf7
    5 N505bbc388c314163a614e26c42dbedb3
    6 N551ffce0f2d841b9b5c135f3d29fcfd2
    7 N707015943edb4147ac70231baeac0bf4
    8 N822c5bf0fc19421188cff99124254aa3
    9 N87376d5cf4a04025a09e81d077f343d9
    10 N886b1b8b4c294c17a8f1c7baceb3fec4
    11 N88c3bbd280b74caf903e8e60e7a462c1
    12 N97ddb00176bb40bbb1469c674476358a
    13 Nae805bd9a56a4d2f8a673b8ca20aa0a8
    14 Nc98594e9e9494b98882c6820c1f79959
    15 Ncdbc4332bf8e4ef9a586a8e979d9dbc7
    16 Nf4e6d709854a471d86864e68c24be627
    17 Nff265f73be0c41d3809e3e41cb8b3be3
    18 anzsrc-for:11
    19 anzsrc-for:1103
    20 anzsrc-for:1111
    21 schema:author N4829056aa6af43458b82cdcdb5471a00
    22 schema:citation sg:pub.10.1007/s00702-003-0007-9
    23 sg:pub.10.1007/s10616-006-9038-z
    24 sg:pub.10.1007/s11920-013-0367-2
    25 sg:pub.10.1007/s12603-011-0339-3
    26 sg:pub.10.1007/s12603-012-0097-x
    27 sg:pub.10.1007/s12603-012-0385-5
    28 sg:pub.10.1023/a:1008852127668
    29 sg:pub.10.1023/a:1011603916962
    30 sg:pub.10.1023/a:1025628925796
    31 sg:pub.10.1038/nature04598
    32 sg:pub.10.1038/nn1908
    33 schema:datePublished 2013-11-04
    34 schema:datePublishedReg 2013-11-04
    35 schema:description Synaptic loss correlates closely with cognitive deficits in Alzheimer’s disease and represents a new target for intervention. Souvenaid® is the first medical nutrition product to be designed to support synapse formation and function in early Alzheimer’s disease, and has undergone an extensive, 12-year development programme. The relatively large amount of clinical data available for Souvenaid® is unusual for a medical nutrition product. Souvenaid® contains omega-3 polyunsaturated fatty acids (docosahexaenoic acid and eicosapentaenoic acid), uridine (as uridine monophosphate) and choline which are nutritional precursors required for synaptic membrane phospholipid synthesis, together with phospholipids and other cofactors. Souvenaid® has demonstrated cognitive benefits in patients with mild Alzheimer’s disease but not in patients with mild-to-moderate Alzheimer’s disease. Two randomised, double-blind, controlled trials (duration 12 and 24 weeks) in patients with mild Alzheimer’s disease untreated with acetylcholinesterase inhibitors and/or memantine have demonstrated that Souvenaid® is well tolerated and improves episodic memory performance. The daily intake of Souvenaid® has not been associated with any harmful effects or interactions with medications and none are anticipated. The ongoing, 24-month, European Union-funded LipiDiDiet trial in subjects with prodromal Alzheimer’s disease is evaluating the potential benefits of Souvenaid® on memory and in slowing progression to Alzheimer’s dementia. If Souvenaid® induces synaptogenesis and improved synaptic function, it may provide benefits in other clinical conditions characterised by neurodegeneration. A number of trials are ongoing and planned to evaluate the potential wider benefits of Souvenaid®.
    36 schema:genre article
    37 schema:inLanguage en
    38 schema:isAccessibleForFree false
    39 schema:isPartOf Nbe53f7bcf12d429489196cf5a523f9af
    40 Neaf86aba5faa419e83c7d449243f4ee2
    41 sg:journal.1021574
    42 schema:keywords Alzheimer's dementia
    43 Alzheimer's disease
    44 Controlled Trials
    45 European Union
    46 LipiDiDiet trial
    47 Souvenaid
    48 Union
    49 acetylcholinesterase inhibitors
    50 acid
    51 amount
    52 approach
    53 benefits
    54 choline
    55 clinical conditions
    56 clinical data
    57 cofactor
    58 cognitive benefits
    59 cognitive deficits
    60 conditions
    61 daily intake
    62 data
    63 deficits
    64 dementia
    65 development programs
    66 disease
    67 early Alzheimer's disease
    68 effect
    69 episodic memory performance
    70 fatty acids
    71 first medical nutrition product
    72 formation
    73 function
    74 harmful effects
    75 induces synaptogenesis
    76 inhibitors
    77 intake
    78 interaction
    79 intervention
    80 large amount
    81 loss
    82 management
    83 medical nutrition products
    84 medications
    85 memantine
    86 membrane phospholipid synthesis
    87 memory
    88 memory performance
    89 mild
    90 mild Alzheimer's disease
    91 moderate Alzheimer's disease
    92 neurodegeneration
    93 new approach
    94 new targets
    95 number
    96 number of trials
    97 nutrition products
    98 nutritional precursors
    99 patients
    100 performance
    101 phospholipid synthesis
    102 phospholipids
    103 potential benefits
    104 potential wider benefits
    105 precursors
    106 prodromal Alzheimer's disease
    107 products
    108 program
    109 progression
    110 subjects
    111 synapse formation
    112 synaptic function
    113 synaptic loss
    114 synaptic membrane phospholipid synthesis
    115 synaptogenesis
    116 synthesis
    117 target
    118 trials
    119 uridine
    120 wider benefits
    121 schema:name Souvenaid®: A new approach to management of early Alzheimer’s disease
    122 schema:pagination 291-299
    123 schema:productId N40f6a42714884dbab8397779e55b5247
    124 N5f7d0482316e450080944a100b79f46b
    125 Nb39585e170ce475cb82c0cf422278a26
    126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034591338
    127 https://doi.org/10.1007/s12603-013-0411-2
    128 schema:sdDatePublished 2022-01-01T18:29
    129 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    130 schema:sdPublisher N449a128c4455452cab402df773fe25c6
    131 schema:url https://doi.org/10.1007/s12603-013-0411-2
    132 sgo:license sg:explorer/license/
    133 sgo:sdDataset articles
    134 rdf:type schema:ScholarlyArticle
    135 N04d14c2b863d4e1ab3f26e22324231c6 rdf:first N95d0d507235b45cba5496f5202ca9755
    136 rdf:rest N8107e8372ec14831841bf58f34e9596f
    137 N0a07c84e327c41058b74522ed0a7128a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Choline
    139 rdf:type schema:DefinedTerm
    140 N12c075b93b194ef093f98b75fff6b73e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    141 schema:name Memory, Episodic
    142 rdf:type schema:DefinedTerm
    143 N26b38e38ce964a2891aee3e226fe63c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Humans
    145 rdf:type schema:DefinedTerm
    146 N2720059cc4d74e51900321ae48b86c7b rdf:first sg:person.01320561246.23
    147 rdf:rest Nfd5d01ac942d47ac882f34785c7188fe
    148 N40f6a42714884dbab8397779e55b5247 schema:name dimensions_id
    149 schema:value pub.1034591338
    150 rdf:type schema:PropertyValue
    151 N449a128c4455452cab402df773fe25c6 schema:name Springer Nature - SN SciGraph project
    152 rdf:type schema:Organization
    153 N4829056aa6af43458b82cdcdb5471a00 rdf:first sg:person.0715446716.30
    154 rdf:rest N04d14c2b863d4e1ab3f26e22324231c6
    155 N4b2ba9e7b54f4960a5a9a6506857baf7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Docosahexaenoic Acids
    157 rdf:type schema:DefinedTerm
    158 N505bbc388c314163a614e26c42dbedb3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Cholinesterase Inhibitors
    160 rdf:type schema:DefinedTerm
    161 N551ffce0f2d841b9b5c135f3d29fcfd2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Double-Blind Method
    163 rdf:type schema:DefinedTerm
    164 N5f7d0482316e450080944a100b79f46b schema:name pubmed_id
    165 schema:value 24626757
    166 rdf:type schema:PropertyValue
    167 N707015943edb4147ac70231baeac0bf4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    168 schema:name Prodromal Symptoms
    169 rdf:type schema:DefinedTerm
    170 N8107e8372ec14831841bf58f34e9596f rdf:first Nfbe10642f4544349aaa144675383f295
    171 rdf:rest Nc228fda7e0c34497bd3cd4e91412d995
    172 N822c5bf0fc19421188cff99124254aa3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Randomized Controlled Trials as Topic
    174 rdf:type schema:DefinedTerm
    175 N87376d5cf4a04025a09e81d077f343d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Eicosapentaenoic Acid
    177 rdf:type schema:DefinedTerm
    178 N886b1b8b4c294c17a8f1c7baceb3fec4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Uridine Monophosphate
    180 rdf:type schema:DefinedTerm
    181 N88c3bbd280b74caf903e8e60e7a462c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Male
    183 rdf:type schema:DefinedTerm
    184 N95d0d507235b45cba5496f5202ca9755 schema:affiliation grid-institutes:None
    185 schema:familyName Bajwa
    186 schema:givenName J.
    187 rdf:type schema:Person
    188 N97ddb00176bb40bbb1469c674476358a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    189 schema:name Memantine
    190 rdf:type schema:DefinedTerm
    191 Na3bb4a49b70f476d8bb7f5f1901dd93b rdf:first sg:person.0751705456.81
    192 rdf:rest rdf:nil
    193 Nae805bd9a56a4d2f8a673b8ca20aa0a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    194 schema:name Synapses
    195 rdf:type schema:DefinedTerm
    196 Nb39585e170ce475cb82c0cf422278a26 schema:name doi
    197 schema:value 10.1007/s12603-013-0411-2
    198 rdf:type schema:PropertyValue
    199 Nbe53f7bcf12d429489196cf5a523f9af schema:volumeNumber 18
    200 rdf:type schema:PublicationVolume
    201 Nc228fda7e0c34497bd3cd4e91412d995 rdf:first sg:person.01056304631.29
    202 rdf:rest N2720059cc4d74e51900321ae48b86c7b
    203 Nc565890fbd0d47ddab1e3bb0f135a586 schema:affiliation grid-institutes:None
    204 schema:familyName Lawton
    205 schema:givenName M.
    206 rdf:type schema:Person
    207 Nc98594e9e9494b98882c6820c1f79959 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    208 schema:name Disease Progression
    209 rdf:type schema:DefinedTerm
    210 Ncdbc4332bf8e4ef9a586a8e979d9dbc7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    211 schema:name Alzheimer Disease
    212 rdf:type schema:DefinedTerm
    213 Nd618d8da723747e4bf1fc04e05d11338 rdf:first sg:person.0603772166.26
    214 rdf:rest Na3bb4a49b70f476d8bb7f5f1901dd93b
    215 Neaf86aba5faa419e83c7d449243f4ee2 schema:issueNumber 3
    216 rdf:type schema:PublicationIssue
    217 Nf4e6d709854a471d86864e68c24be627 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    218 schema:name European Union
    219 rdf:type schema:DefinedTerm
    220 Nfbe10642f4544349aaa144675383f295 schema:affiliation grid-institutes:None
    221 schema:familyName Coleman
    222 schema:givenName G.
    223 rdf:type schema:Person
    224 Nfd5d01ac942d47ac882f34785c7188fe rdf:first Nc565890fbd0d47ddab1e3bb0f135a586
    225 rdf:rest Nd618d8da723747e4bf1fc04e05d11338
    226 Nff265f73be0c41d3809e3e41cb8b3be3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    227 schema:name Female
    228 rdf:type schema:DefinedTerm
    229 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    230 schema:name Medical and Health Sciences
    231 rdf:type schema:DefinedTerm
    232 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    233 schema:name Clinical Sciences
    234 rdf:type schema:DefinedTerm
    235 anzsrc-for:1111 schema:inDefinedTermSet anzsrc-for:
    236 schema:name Nutrition and Dietetics
    237 rdf:type schema:DefinedTerm
    238 sg:journal.1021574 schema:issn 1279-7707
    239 1760-4788
    240 schema:name The journal of nutrition, health & aging
    241 schema:publisher Springer Nature
    242 rdf:type schema:Periodical
    243 sg:person.01056304631.29 schema:affiliation grid-institutes:grid.11918.30
    244 schema:familyName Hope
    245 schema:givenName K.
    246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056304631.29
    247 rdf:type schema:Person
    248 sg:person.01320561246.23 schema:affiliation grid-institutes:grid.416091.b
    249 schema:familyName Jones
    250 schema:givenName R. W.
    251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320561246.23
    252 rdf:type schema:Person
    253 sg:person.0603772166.26 schema:affiliation grid-institutes:grid.451190.8
    254 schema:familyName Marven
    255 schema:givenName M.
    256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603772166.26
    257 rdf:type schema:Person
    258 sg:person.0715446716.30 schema:affiliation grid-institutes:grid.7445.2
    259 schema:familyName Ritchie
    260 schema:givenName C. W.
    261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715446716.30
    262 rdf:type schema:Person
    263 sg:person.0751705456.81 schema:affiliation grid-institutes:grid.4777.3
    264 schema:familyName Passmore
    265 schema:givenName P.
    266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751705456.81
    267 rdf:type schema:Person
    268 sg:pub.10.1007/s00702-003-0007-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042189844
    269 https://doi.org/10.1007/s00702-003-0007-9
    270 rdf:type schema:CreativeWork
    271 sg:pub.10.1007/s10616-006-9038-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1045801968
    272 https://doi.org/10.1007/s10616-006-9038-z
    273 rdf:type schema:CreativeWork
    274 sg:pub.10.1007/s11920-013-0367-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017268113
    275 https://doi.org/10.1007/s11920-013-0367-2
    276 rdf:type schema:CreativeWork
    277 sg:pub.10.1007/s12603-011-0339-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044372203
    278 https://doi.org/10.1007/s12603-011-0339-3
    279 rdf:type schema:CreativeWork
    280 sg:pub.10.1007/s12603-012-0097-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1040649409
    281 https://doi.org/10.1007/s12603-012-0097-x
    282 rdf:type schema:CreativeWork
    283 sg:pub.10.1007/s12603-012-0385-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009103358
    284 https://doi.org/10.1007/s12603-012-0385-5
    285 rdf:type schema:CreativeWork
    286 sg:pub.10.1023/a:1008852127668 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008832069
    287 https://doi.org/10.1023/a:1008852127668
    288 rdf:type schema:CreativeWork
    289 sg:pub.10.1023/a:1011603916962 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047542537
    290 https://doi.org/10.1023/a:1011603916962
    291 rdf:type schema:CreativeWork
    292 sg:pub.10.1023/a:1025628925796 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050886881
    293 https://doi.org/10.1023/a:1025628925796
    294 rdf:type schema:CreativeWork
    295 sg:pub.10.1038/nature04598 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008587713
    296 https://doi.org/10.1038/nature04598
    297 rdf:type schema:CreativeWork
    298 sg:pub.10.1038/nn1908 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041228661
    299 https://doi.org/10.1038/nn1908
    300 rdf:type schema:CreativeWork
    301 grid-institutes:None schema:alternateName Conway Medical Centre, Plumstead, London, UK
    302 London, UK
    303 schema:name Conway Medical Centre, Plumstead, London, UK
    304 London, UK
    305 rdf:type schema:Organization
    306 grid-institutes:grid.11918.30 schema:alternateName Dementia Services Development Centre, University of Stirling, Stirling, UK
    307 schema:name Dementia Services Development Centre, University of Stirling, Stirling, UK
    308 rdf:type schema:Organization
    309 grid-institutes:grid.416091.b schema:alternateName Research Institute for the Care of Older People, Royal United Hospital, Bath, UK
    310 schema:name Research Institute for the Care of Older People, Royal United Hospital, Bath, UK
    311 rdf:type schema:Organization
    312 grid-institutes:grid.451190.8 schema:alternateName Oxford Health NHS Foundation Trust, Oxford, UK
    313 schema:name Oxford Health NHS Foundation Trust, Oxford, UK
    314 rdf:type schema:Organization
    315 grid-institutes:grid.4777.3 schema:alternateName Centre for Public Health, Queens University, Belfast, UK
    316 schema:name Centre for Public Health, Queens University, Belfast, UK
    317 rdf:type schema:Organization
    318 grid-institutes:grid.7445.2 schema:alternateName Department of Medicine, Imperial College, London, UK
    319 schema:name Department of Medicine, Imperial College, London, UK
    320 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...